Enasidenib companion diagnostic

Drug Profile

Enasidenib companion diagnostic

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories; Celgene Corporation
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute myeloid leukaemia

Most Recent Events

  • 12 Oct 2016 Celgene and Abbott enter into a collaboration agreement to develop and commercialise enasidenib companion diagnostic
  • 12 Oct 2016 Phase-III clinical trials in Acute myeloid leukaemia (Diagnosis) in Taiwan, Spain, Turkey, Russia, South Korea, Italy, Germany, France, France, France, Denmark, Czech Republic, Canada, Belgium, Austria, Australia, United Kingdom, USA (unspecified route) (NCT02577406)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top